STA
TEVA icon

Summit Trail Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Summit Trail Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$620K Buy
18,286
+4,756
+35% +$158K 0.01% 1159
2026
Q1 		$408K Buy
+13,530
New +$435K 0.01% 1226
2018
Q1 		– Sell
-2,029
Closed -$42K – 1525
2017
Q4 		$42K Buy
+2,029
New +$30.5K 0.01% 860

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Summit Trail Advisors's TEVA Position: Q2 2026 in Review

Summit Trail Advisors increased its Teva Pharmaceuticals (TEVA) stake by 35% in Q2 2026, buying an estimated $158K and bringing the position to 18,286 shares worth $620K. The position accounts for 0.01% of the portfolio, ranked #1159.

Summit Trail Advisors first reported a position in TEVA in Q4 2017 and has held it in 3 quarters since. 675 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Summit Trail Advisors held 18,286 shares of Teva Pharmaceuticals worth $620K as of Q2 2026.
  • Summit Trail Advisors bought 4,756 Teva Pharmaceuticals shares in Q2 2026, an estimated $158K.
  • Teva Pharmaceuticals made up 0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1159 holding.
  • Summit Trail Advisors first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 3 quarters since.
  • 675 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.